Passage BIO, Inc. (PASG) · Nov 18, 2026 · Delisting
Nasdaq deficiency — $50,000 equity vs $2.5 million requirement
Passage Bio received a Nasdaq delisting notice after its equity fell to $50,000. The Remix merger is now the company’s path back to compliance.
Passage Bio is a cash-constrained shell transitioning into Remix Therapeutics. The company has been winding down its gene-therapy programs and relying on the planned Remix merger as its strategic reset; its September 30, 2026 filing said its ability to continue as a going concern depended on completing that merger or obtaining substantial additional funding. Passage shareholders approved the merger-related proposals on November 5, 2026, so the transaction was already the expected route forward before this filing.
The new information is a formal Nasdaq compliance failure, not a surprise deterioration in the operating business. Nasdaq requires at least $2.5 million of stockholders’ equity, while Passage reported only $50,000 at September 30, leaving it far below the threshold and without the alternative market-value or income qualification. 〔0〕
| Metric | Reported | Requirement |
|---|---|---|
| Stockholders’ equity (Item 3.01) | $50,000 | $2,500,000 |
The immediate consequence is limited, but the merger is now more operationally important. The notice does not suspend trading, and the company says its shares will continue trading on Nasdaq for now. 〔1〕 But the planned merger—and Nasdaq’s approval of the combined company’s listing—has become the practical bridge between the current balance sheet and continued exchange access. Passage says it expects to regain compliance once the deal closes, but that outcome remains conditional rather than completed. 〔2〕
Bottom line: This is a modestly negative filing because it formalizes a severe capital deficiency, while leaving trading intact and preserving the already-public merger solution. It matters mainly by adding execution risk to a transaction the company already needs to complete.
Merger closing and Nasdaq listing approval
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!